Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo MI, Cheng EH (2016) Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: a braided cancer river model of kidney cancer. Semin Cell Dev Biol. doi:10.1016/j.semcdb.2016.09.002. pii: S1084-9521(16)30286-5
PubMed
Google Scholar
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260):23–28
Article
CAS
PubMed
Google Scholar
Yates LR, Campbell PJ (2012) Evolution of the cancer genome. Nat Rev Genet 13(11):795–806
Article
CAS
PubMed
PubMed Central
Google Scholar
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892
Article
CAS
PubMed
PubMed Central
Google Scholar
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357
Article
CAS
PubMed
PubMed Central
Google Scholar
Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4(127):127ps10
Article
PubMed
Google Scholar
Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9(1):28–39
Article
PubMed
Google Scholar
Longo DL (2012) Tumor heterogeneity and personalized medicine. N Engl J Med 366(10):956–957
Article
CAS
PubMed
Google Scholar
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Article
CAS
PubMed
Google Scholar
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Article
CAS
PubMed
Google Scholar
Wei EY, Hsieh JJ (2015) A river model to map convergent cancer evolution and guide therapy in RCC. Nat Rev Urol 12(12):706–712
Article
CAS
PubMed
Google Scholar
Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119–1132
Article
CAS
PubMed
Google Scholar
Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F et al (2016) Third-line targeted therapy in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol. doi:10.1016/j.eururo.2016.05.049. pii: S0302-2838(16)30258-5
Google Scholar
Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF et al (2014) Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clini Cancer Res 20(7):1955–1964
Article
CAS
Google Scholar
Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, De Velasco G et al (2016) Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res 22(10):2445–2452
Article
CAS
PubMed
Google Scholar
Voss MH, Hsieh JJ (2016) Therapeutic Guide for mTOuRing through the braided kidney cancer genomic river. Clin Cancer Res 22(10):2320–2322
Article
CAS
PubMed
Google Scholar
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473–1482
Article
CAS
PubMed
Google Scholar
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1814–1823
Article
CAS
PubMed
PubMed Central
Google Scholar
Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT et al (2016) Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol. doi:10.1200/JCO.2016.67.9084. pii: JCO679084
Google Scholar
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813
Article
CAS
PubMed
Google Scholar